File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: In vivo osteoprotegerin gene therapy preventing bone loss induced by periodontitis

TitleIn vivo osteoprotegerin gene therapy preventing bone loss induced by periodontitis
Authors
Issue Date2015
PublisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0022-3484&site=1
Citation
Journal of Periodontal Research, 2015, v. 50 n. 4, p. 434-443 How to Cite?
AbstractObjective The objective of this study was to investigate the effects of osteoprotegerin (OPG) gene therapy on alveolar bone resorption caused by experimental periodontitis in rats, thus forming a foundation for potential clinical applications of OPG gene therapy in the treatment of periodontitis and peri-implantitis. Material and Methods To study the effects of OPG on alveolar bone protection, an experimental periodontitis model was used by placing a bacterial plaque retentive silk ligature in the gingival sulcus around the maxillary second molar tooth, injection of Porphyromonas gingivalis and high carbohydrate diet. A total of 30 Sprague–Dawley rats were randomly divided into three groups, with 10 rats in each group: group I (control) was treated with 10 μL normal saline injection; group II with 10 μL mock vector; and group III with 10 μL local OPG gene transfer by transfection with in vitro constructed pcDNA3.1-human OPG (pcDNA3.1-hOPG). A subperiosteal injection was done adjacent to the second molars on days 0, 7, 14 and 21. Four weeks later, all animals were killed and radiographic, histological and immunohistochemical examinations were performed. Statistical analysis included ANOVA and LSD-Bonferroni test. Results Group III (OPG gene therapy) had significantly enhanced (p < 0.05) integrated optical density of OPG, had significantly decreased alveolar bone resorption volume and active osteoclast number (p < 0.05) through descriptive histological examination when compared with the other two groups at week 4. Conclusion Local recombinant OPG plasmid-mediated gene therapy suppresses osteoclastogenesis in vivo and inhibits alveolar bone height reduction caused by experimental periodontitis in rats. OPG gene therapy may be beneficial in preventing progressive periodontal bone loss.
Persistent Identifierhttp://hdl.handle.net/10722/200413
ISSN
2015 Impact Factor: 2.474
2015 SCImago Journal Rankings: 0.932

 

DC FieldValueLanguage
dc.contributor.authorTang, H-
dc.contributor.authorMattheos, N-
dc.contributor.authorYao, Y-
dc.contributor.authorJia, Y-
dc.contributor.authorMa, L-
dc.contributor.authorGong, P-
dc.date.accessioned2014-08-21T06:45:17Z-
dc.date.available2014-08-21T06:45:17Z-
dc.date.issued2015-
dc.identifier.citationJournal of Periodontal Research, 2015, v. 50 n. 4, p. 434-443-
dc.identifier.issn0022-3484-
dc.identifier.urihttp://hdl.handle.net/10722/200413-
dc.description.abstractObjective The objective of this study was to investigate the effects of osteoprotegerin (OPG) gene therapy on alveolar bone resorption caused by experimental periodontitis in rats, thus forming a foundation for potential clinical applications of OPG gene therapy in the treatment of periodontitis and peri-implantitis. Material and Methods To study the effects of OPG on alveolar bone protection, an experimental periodontitis model was used by placing a bacterial plaque retentive silk ligature in the gingival sulcus around the maxillary second molar tooth, injection of Porphyromonas gingivalis and high carbohydrate diet. A total of 30 Sprague–Dawley rats were randomly divided into three groups, with 10 rats in each group: group I (control) was treated with 10 μL normal saline injection; group II with 10 μL mock vector; and group III with 10 μL local OPG gene transfer by transfection with in vitro constructed pcDNA3.1-human OPG (pcDNA3.1-hOPG). A subperiosteal injection was done adjacent to the second molars on days 0, 7, 14 and 21. Four weeks later, all animals were killed and radiographic, histological and immunohistochemical examinations were performed. Statistical analysis included ANOVA and LSD-Bonferroni test. Results Group III (OPG gene therapy) had significantly enhanced (p < 0.05) integrated optical density of OPG, had significantly decreased alveolar bone resorption volume and active osteoclast number (p < 0.05) through descriptive histological examination when compared with the other two groups at week 4. Conclusion Local recombinant OPG plasmid-mediated gene therapy suppresses osteoclastogenesis in vivo and inhibits alveolar bone height reduction caused by experimental periodontitis in rats. OPG gene therapy may be beneficial in preventing progressive periodontal bone loss.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0022-3484&site=1-
dc.relation.ispartofJournal of Periodontal Research-
dc.titleIn vivo osteoprotegerin gene therapy preventing bone loss induced by periodontitis-
dc.typeArticle-
dc.identifier.emailTang, H: tanghua@hku.hk-
dc.identifier.emailMattheos, N: mattheos@hku.hk-
dc.identifier.authorityMattheos, N=rp01662-
dc.identifier.doi10.1111/jre.12224-
dc.identifier.scopuseid_2-s2.0-84935756067-
dc.identifier.hkuros232871-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats